A case-control study to find out the prevalence of metabolic syndrome in patients with psoriasis as compared to age and sex matched controls
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20214547Keywords:
Case-control study, Psoriasis, Metabolic syndromeAbstract
Background: Psoriasis is an immune mediated chronic inflammatory dermatosis and it is associated with high risk of cardiovascular events. Aim of the study was to estimate the prevalence of metabolic syndrome and its association with disease severity in patients with psoriasis.
Methods: This was a case control study which included 150 cases of chronic plaque psoriasis and 150 healthy controls. All subjects underwent detailed history and clinical examination including measurement of blood pressure and waist circumference and psoriasis area and severity index (PASI) score. Fasting blood sugar, triglyceride, cholesterol, and high-density lipoprotein cholesterol levels were tested following overnight fasting. Various parameters of metabolic syndrome were compared in two groups using chi square test and fisher’s exact test. Statistical analysis of the data was done using epi-info TM software.
Results: Prevalence of metabolic syndrome was more common in patients of psoriasis than in control (56.67% vs. 17.33%; p<0.0001). Psoriatic patients had higher prevalence of abdominal obesity (57.33% vs. 27.33%; p=0.0037), elevated blood pressure (32% vs. 12%; p=0.0001), elevated fasting blood sugar level (62% vs. 22%; p<0.0001), hypertriglyceridemia (44.66% vs. 32%; p=0.0326), low level of HDL cholesterol (64% vs. 21.33%; p<0.0001 and alcohol abuse (22.22% vs. 14.66%; p=0.0154).
Conclusions: The findings in our study demonstrated a robust association between psoriasis and metabolic syndrome and its components, irrespective of psoriasis severity.
References
Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol. 2008;20(4):416-22.
Menter A, Griffiths C, Tebbey P, Horn E, Sterry W, on behalf of the International Psoriasis Council. Exploring the association between cardiovascular and other disease related risk factors in the psoriasis population: The need for increased understanding across the medical community. J Eur Acad Dermatol Venereol. 2010;24:1371-7.
Greb JE, Goldminz AM, Elder JT. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.
Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit. 2005;11:155-62.
Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298:321-8.
Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol. 2012;39(3):212-8.
Sawant A, Mankeshwar R, Shah S, Raghavan R, Dhongde G, Raje H. Prevalence of metabolic syndrome in urban India. Cholesterol. 2011;2011:920983.
Davidovici BB, Sattar N, Prinz JC, Puig L, Emery P, Barker JN et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785-96.
Madanagobalane S, Anandan S. Prevalence of metabolic syndrome in south Indian patients with psoriasis vulgaris and the relation between disease severity and metabolic syndrome. A hospital-based case control study. Indian J Dermatol. 2012;57:353-7.
Lakshmi S, Nath AK, Udayashankar C. Metabolic syndrome in patients with psoriasis: A comparative study. Indian Dermatol Online J. 2014;5:132-37.
Gisondi P, Tessari G, Conti A. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br J Dermatol. 2007;157:68-73.
Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157:68-73.
Cohen AD, Drieher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B et al. Psoriasis and diabetes: A population based cross sectional study. J Eur Acad Dermatol Venerol. 2008;22:585-9.
Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol. 2011;147:419-24.
Gopal MG, Talwar A, Sharath Kumar BC, Ramesh M, Nandini AS. A clinical and epidemiological study of psoriasis and its association with various biochemical parameters in newly diagnosed cases. J Clin Diagn Res. 2013;7:2901-03.
Khunger N, Gupta D, Ramesh V. Is psoriasis a new cutaneous marker for metabolic syndrome? A study in Indian patients. Indian J Dermatol. 2013;58(4):313-4.
Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol. 2010;76(6):662-5.
Misra A, Khurana L. The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. Metab Syndr Relat Disord. 2009;7(6):497-514.
Shapiro J, Cohen AD, Weitzman D, Tal R, David M. Psoriasis and cardiovascular risk factors: Acase-control study on inpatients comparing psoriasis to dermatitis. J Am Acad Dermatol. 2012;66:252-8.
Pietrzak A, Kadzielewski J, Janowski K, Rolinski J, Krasowska D, Chodorowska G et al. Lipoprotein in patients with psoriasis: Associations with lipid profiles and disease severity. Int J Dermatol. 2009;48:379-87.
Goolam Mahyoodeen N, Crowther NJ, Snyman T, Pillay L, Tikly M. High burden of the metabolic syndrome and its component disorders in South Africans with psoriasis. Int J Dermatol. 2019;58 (5):557-62.
Salunke AS, Nagargoje MV, Belgaumkar VA, Tolat SN, Chavan RB Association of metabolic syndrome in chronic plaque psoriasis patients and their correlation with disease severity, duration and age: a case control study from Western Maharashtra. J Clin Diagn Res. 2017;11(8):WC06-10.
Gui XY, Yu XL, Jin HZ, Zuo YG, Wu C. Prevalence of metabolic syndrome in Chinese psoriasis patients: a hospital-based cross-sectional study. J Diabetes Investig. 2018;9(1):39-43.
